LORAZEPAM SUBLINGUAL 0.5 MG — DIN 02410745
LORAZEPAM : 0.5 MG · AA PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is LORAZEPAM SUBLINGUAL?
LORAZEPAM SUBLINGUAL 0.5 MG contains LORAZEPAM : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02410745, held by AA PHARMA INC, supplied as TABLET for SUBLINGUAL administration. Health Canada currently lists it as marketed, status dated 15-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LORAZEPAM SUBLINGUAL used for?
Short-term relief of manifestations of excessive anxiety in anxiety neurosis; adjunct for relief of excessive anxiety prior to surgical interventions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lorazepam cost around the world?
Lorazepam is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Brazil publishes a preco fabrica (ex-factory ceiling); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 61 | USD███.██ |
| Spain | PVP con IVA (public price) | 22 | 22 | EUR███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 11 | NOK███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 3 | 9 | BRL███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| South Africa | single exit price | 6 | 8 | ZAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 5 | SEK███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Morocco | PPV (public price) | 2 | 4 | MAD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 3 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
155 pack listings across 76 brand entries and 15 price bases, refreshed 07 Sep 2026. Ranges span every Lorazepam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Lorazepam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
16 holders have a Canadian DIN containing Lorazepam, across 53 DINs, of which 17 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 3 | NTP-LORAZEPAM, TEVA-LORAZEPAM | Sourceable in Canada |
| AA PHARMA INC | 3 | 3 | LORAZEPAM SUBLINGUAL | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-LORAZEPAM | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 3 | PMS-LORAZEPAM | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | PRO-LORAZEPAM | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | LORAZEPAM INJECTION USP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | LORAZEPAM INJECTION, USP | Sourceable in Canada |
| PFIZER CANADA ULC | 7 | 0 | ATIVAN, LORAZEPAM INJECTION USP | No marketed DIN |
| WYETH LTD. | 6 | 0 | ATIVAN INJ 4MG/ML, ATIVAN SUBL TAB 0.5MG, ATIVAN SUBL TAB 1MG, ATIVAN TAB 0.5MG, ATIVAN TAB 1MG, +1 more | No marketed DIN |
| NU-PHARM INC | 3 | 0 | NU-LORAZ TAB 0.5MG, NU-LORAZ TAB 1MG, NU-LORAZ TAB 2MG | No marketed DIN |
| SANIS HEALTH INC | 3 | 0 | LORAZEPAM | No marketed DIN |
| SIVEM PHARMACEUTICALS ULC | 3 | 0 | LORAZEPAM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | SUBLINGUAL |
| Pack configuration (monograph) | Bottles of 100 and 500 tablets. |
| Storage | Not explicitly stated in provided text (Section 11 header present but content missing). Standard practice is 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lorazepam |
|---|---|
| ATC code | N05BA06 |
| AHFS class | 28:24.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02410745 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2410745 |
| Brand name | LORAZEPAM SUBLINGUAL |
| Generic / active ingredient | LORAZEPAM : 0.5 MG |
| Market authorization holder | AA PHARMA INC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA06 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BA |
| Current status | MARKETED |
| Status date | 15-Jan-2018 |
| Original market date | 2013-10-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualized dosage. Anxiety: 2-3 mg/day in divided doses (max 6 mg). Pre-surgery: 0.05 mg/kg (max 4 mg) sublingually 1-2 hours before. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Myasthenia gravis, acute narrow angle glaucoma, known hypersensitivity to benzodiazepines or any ingredient in the formulation.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and life-threatening withdrawal. Concomitant use with opioids may cause fatal respiratory depression. Risk of falls/fractures.
Is Lorazepam in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
17 of 53 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LORAZEPAM | 1 MG | TABLET | APOTEX INC | MARKETED | 00655759 |
| APO-LORAZEPAM | 0.5 MG | TABLET | APOTEX INC | MARKETED | 00655740 |
| APO-LORAZEPAM | 2 MG | TABLET | APOTEX INC | MARKETED | 00655767 |
| LORAZEPAM INJECTION USP | 4 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02243278 |
| LORAZEPAM INJECTION, USP | 4 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02550962 |
| LORAZEPAM SUBLINGUAL | 1 MG | TABLET | AA PHARMA INC | MARKETED | 02410753 |
| LORAZEPAM SUBLINGUAL | 2 MG | TABLET | AA PHARMA INC | MARKETED | 02410761 |
| PMS-LORAZEPAM | 1 MG | TABLET | PHARMASCIENCE INC | MARKETED | 00728195 |
| PMS-LORAZEPAM | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | 00728209 |
| PMS-LORAZEPAM | 0.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | 00728187 |
2 · Same class — other molecules in ATC N05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lorazepam | APO-LORAZEPAM · ATIVAN · ATIVAN INJ 4MG/ML · ATIVAN INJECTION LIQ 4MG/ML · +21 more | 53 | 17 | Yes |
| Alprazolam | ALPRAZOLAM · ALPRAZOLAM TABLETS 0.25 · ALPRAZOLAM TABLETS 0.5MG · APO-ALPRAZ · +17 more | 50 | 13 | Yes |
| Oxazepam | APO-OXAZEPAM · BIO-OXAZEPAM · NOVOXAPAM TAB 10MG · NOVOXAPAM TAB 15MG · +17 more | 31 | 9 | Yes |
| Diazepam | BIO-DIAZEPAM · DIASTAT · DIAZEMULS · DIAZEPAM · +23 more | 38 | 8 | Yes |
| Bromazepam | ALTI-BROMAZEPAM 1.5MG TABLETS · ALTI-BROMAZEPAM 3MG TABLETS · ALTI-BROMAZEPAM 6MG TABLETS · APO-BROMAZEPAM · +14 more | 24 | 4 | Yes |
| Clorazepate Potassium | CLORAZEPATE · NOVO-CLOPATE CAP 15MG · NOVO-CLOPATE CAP 3.75MG · NOVO-CLOPATE CAP 7.5MG · +3 more | 9 | 3 | Yes |
| Clobazam | APO-CLOBAZAM · CLOBAZAM-10 · DOM-CLOBAZAM · FRISIUM TAB 10MG · +6 more | 10 | 2 | Yes |
| Chlordiazepoxide | CHLORDIAZEPOXIDE · CHLORDIAZEPOXIDE CAP 10MG · CHLORDIAZEPOXIDE CAP 5MG · CHLORDIAZEPOXYDE 25 CAP · +10 more | 16 | 1 | Yes |
| Ketazolam | LOFTRAN CAP 30MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BE | Buspirone | 25 | 7 |
| N05BB | Hydroxyzine | 29 | 5 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LORAZEPAM SUBLINGUAL called?
The same molecule, Lorazepam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Rativor | Latin | Norway |
| LORAZEPAM | Latin | Brazil, Lebanon |
| Lorazepam Orion | Latin | Sweden |
| LORAX | Latin | Brazil |
| Lorazepam Orifarm | Latin | Norway |
| LORAZEPAM PHARMA | Latin | Morocco |
| TEMESTA | Latin | Morocco |
| Temesta® | Latin | Sweden |
| Tranqipam | Latin | South Africa |
| Ativan Injection | Latin | South Africa |
| Lorazepam Macure | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.